Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).
Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.
Read the report
You may be interested in
Australia’s CAPEX falters in Q1, with cost inflation to test activity
Private new capital expenditure fell 0.3% q/q in Q1 2022, led lower by a fall in buildings and structures investment. The weak result is in part due to the impact of Omicron on labour availability, and the postponement of construction activity in flood affected areas. Machinery & equipment volumes rose in the quarter.Find Out More
LandAid’s 10K Challenge
Yesterday, members of Oxford Economics joined LandAid’s 10k run in Regents Park London to raise awareness and funds for young people experiencing homelessness.Find Out More
Anchors away – RBA change course and raise rates
The RBA has opted to raise the cash rate target to 0.35%. For some time, the RBA identified faster wage growth as its trigger for raising rates. Official data sources have provided no new information on this front over the past month. But the board has put their faith in information from the RBA business liaison program that wage growth is picking up.Find Out More